For example, only a few phase I/II trials have validated the safety of ginsenosides (e.g., GRb1 alone or combined with YN-3 probiotic intervention in mild ALD), but with limited sample sizes (n < 100), shorter duration of treatment (≤12 weeks), and lack of long-term follow-up data on endpoints with hard indicators (e.g., rate of reversal of hepatic fibrosis, incidence of HCC). Here, PIK3R1 is linked to hepatocellular carcinoma.